Literature DB >> 15145555

Early glial responses in murine models of multiple sclerosis.

Margaret M Ayers1, Lisa J Hazelwood, Deanne V Catmull, Dongwei Wang, Quinn McKormack, Claude C A Bernard, Jacqueline M Orian.   

Abstract

Investigations of functional interactions among axons and glia over the last decade have revealed the extent and complexity of glial-neuronal and glial-glial communication during development, adult function and recovery from injury. These data have profound implications for the understanding of central nervous system (CNS) disorders, which until recently, have been classified as either neuronal or glial diseases. Re-evaluation of the pathological processes in a number of conditions has clearly shown involvement of both neurons and glia in early pathology. In multiple sclerosis (MS), the myelin sheath has traditionally been regarded as the primary target. However, recent evidence has clearly demonstrated axonal damage in new lesions. We have addressed the question of the role of axonal pathology in early MS by using well-characterized murine models for the relapsing-remitting (RR) or the primary progressive (PP) forms of the disease. We performed a histopathological survey of the CNS, following induction of the disease, to determine the timing of appearance, as well as the development of lesions. Then we analysed the relationship between inflammation, demyelination and axonal damage together with responses from astrocytes and microglia in each model from the earliest evidence of inflammation. We found that axonal damage begins well ahead of the appearance of motor symptoms. Pathology appears to be more closely related to the degree of inflammation than to demyelination. We also show that early astrocyte responses and the degree of axonal loss are markedly different in the two models and relate to the severity of pathology. These data support the now widely accepted hypothesis that axonal damage begins early in the disease process, but also suggest modulation of axonal loss and disease progression by the astrocytic response.

Entities:  

Mesh:

Year:  2004        PMID: 15145555     DOI: 10.1016/j.neuint.2003.08.018

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  13 in total

1.  Limiting Neuronal Nogo Receptor 1 Signaling during Experimental Autoimmune Encephalomyelitis Preserves Axonal Transport and Abrogates Inflammatory Demyelination.

Authors:  Jae Young Lee; Min Joung Kim; Speros Thomas; Viola Oorschot; Georg Ramm; Pei Mun Aui; Yuichi Sekine; Devy Deliyanti; Jennifer Wilkinson-Berka; Be'eri Niego; Alan R Harvey; Paschalis Theotokis; Catriona McLean; Stephen M Strittmatter; Steven Petratos
Journal:  J Neurosci       Date:  2019-05-06       Impact factor: 6.167

2.  Transgenic inhibition of astroglial NF-kappa B improves functional outcome in experimental autoimmune encephalomyelitis by suppressing chronic central nervous system inflammation.

Authors:  Roberta Brambilla; Trikaldarshi Persaud; Xianchen Hu; Shaffiat Karmally; Valery I Shestopalov; Galina Dvoriantchikova; Dmitry Ivanov; Lubov Nathanson; Scott R Barnum; John R Bethea
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

3.  Initiation and progression of axonopathy in experimental autoimmune encephalomyelitis.

Authors:  Athena M Soulika; Eunyoung Lee; Erica McCauley; Laird Miers; Peter Bannerman; David Pleasure
Journal:  J Neurosci       Date:  2009-11-25       Impact factor: 6.167

Review 4.  Multiple sclerosis and regulatory T cells.

Authors:  Cristina Maria Costantino; Clare Baecher-Allan; David A Hafler
Journal:  J Clin Immunol       Date:  2008-09-02       Impact factor: 8.317

5.  VCAM-1-targeted magnetic resonance imaging reveals subclinical disease in a mouse model of multiple sclerosis.

Authors:  Sébastien Serres; Silvy Mardiguian; Sandra J Campbell; Martina A McAteer; Asim Akhtar; Alexandre Krapitchev; Robin P Choudhury; Daniel C Anthony; Nicola R Sibson
Journal:  FASEB J       Date:  2011-09-09       Impact factor: 5.191

Review 6.  Dynamic glial response and crosstalk in demyelination-remyelination and neurodegeneration processes.

Authors:  Tianci Chu; Lisa B E Shields; Wenxin Zeng; Yi Ping Zhang; Yuanyi Wang; Gregory N Barnes; Christopher B Shields; Jun Cai
Journal:  Neural Regen Res       Date:  2021-07       Impact factor: 5.135

Review 7.  Microglia-Induced Maladaptive Plasticity Can Be Modulated by Neuropeptides In Vivo.

Authors:  Stefano Morara; Anna Maria Colangelo; Luciano Provini
Journal:  Neural Plast       Date:  2015-07-26       Impact factor: 3.599

8.  Treatment with the antipsychotic agent, risperidone, reduces disease severity in experimental autoimmune encephalomyelitis.

Authors:  David O'Sullivan; Laura Green; Sarrabeth Stone; Pirooz Zareie; Marie Kharkrang; Dahna Fong; Bronwen Connor; Anne Camille La Flamme
Journal:  PLoS One       Date:  2014-08-12       Impact factor: 3.240

9.  Immunomodulation Eliminates Inflammation in the Hippocampus in Experimental Autoimmune Encephalomyelitis, but Does Not Ameliorate Anxiety-Like Behavior.

Authors:  Pece Kocovski; Nuzhat Tabassum-Sheikh; Stephanie Marinis; Phuc T Dang; Matthew W Hale; Jacqueline M Orian
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

10.  Molecular grafting onto a stable framework yields novel cyclic peptides for the treatment of multiple sclerosis.

Authors:  Conan K Wang; Christian W Gruber; Maša Cemazar; Christopher Siatskas; Prascilla Tagore; Natalie Payne; Guizhi Sun; Shunhe Wang; Claude C Bernard; David J Craik
Journal:  ACS Chem Biol       Date:  2013-11-07       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.